Profile data is unavailable for this security.
About the company
AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.
- Revenue in USD (TTM)50.70m
- Net income in USD-44.82m
- Incorporated2020
- Employees207.00
- LocationAVITA Medical Inc28159 Avenue Stanford, Suite 220VALENCIA 91355United StatesUSA
- Phone+1 (661) 367-9170
- Websitehttps://www.avitamedical.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Telomir Pharmaceuticals Inc | 0.00 | -18.84m | 199.57m | 1.00 | -- | 66.16 | -- | -- | -0.6889 | -0.6889 | 0.00 | 0.1019 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.8986 | 0.00 | -- | -- | -- | -1,430.39 | -- | -- | -- |
| INmune Bio Inc | 131.00k | -34.50m | 200.00m | 11.00 | -- | 6.25 | -- | 1,526.72 | -1.92 | -1.92 | 0.0073 | 1.62 | 0.0022 | -- | 0.0535 | 11,909.09 | -57.11 | -37.82 | -74.12 | -41.86 | -- | -- | -26,333.59 | -14,901.03 | -- | -16.97 | 0.2044 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
| Compass Therapeutics Inc. | 0.00 | -45.44m | 202.26m | 32.00 | -- | 1.29 | -- | -- | -0.3513 | -0.3513 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -26.03 | -41.75 | -27.21 | -46.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
| Generation Bio Co | 9.96m | -169.06m | 204.24m | 174.00 | -- | 1.55 | -- | 20.50 | -2.56 | -2.56 | 0.1509 | 1.99 | 0.0278 | -- | 10.98 | 57,258.62 | -47.14 | -36.96 | -50.75 | -39.21 | -- | -- | -1,696.87 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
| Acumen Pharmaceuticals Inc | 0.00 | -55.94m | 204.27m | 51.00 | -- | 0.7796 | -- | -- | -1.05 | -1.05 | 0.00 | 4.36 | 0.00 | -- | -- | 0.00 | -22.89 | -- | -23.72 | -- | -- | -- | -- | -- | -- | -- | 0.1034 | -- | -- | -- | -22.20 | -- | -- | -- |
| Scilex Holding Co | 47.05m | -160.60m | 204.74m | 106.00 | -- | -- | -- | 4.35 | -1.28 | -1.28 | 0.3905 | -1.79 | 0.5307 | 5.53 | 1.92 | 448,047.60 | -121.78 | -- | -- | -- | 66.14 | -- | -229.47 | -- | 0.1356 | -12.49 | -- | -- | 22.90 | -- | -614.67 | -- | -- | -- |
| TriSalus Life Sciences Inc | 21.98m | -68.07m | 205.32m | 112.00 | -- | -- | -- | 9.34 | -2.09 | -2.09 | 0.7291 | -1.31 | 1.17 | 1.26 | 7.49 | 196,276.80 | -339.18 | -- | -11,196.50 | -- | 86.74 | -- | -291.08 | -- | 0.714 | -16.82 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
| AVITA Medical Inc | 50.70m | -44.82m | 208.98m | 207.00 | -- | 6.41 | -- | 4.12 | -1.76 | -1.76 | 1.99 | 1.26 | 0.5336 | 1.48 | 8.39 | 244,913.00 | -47.18 | -- | -53.79 | -- | 85.43 | -- | -88.41 | -- | 6.64 | -19.61 | 0.5591 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
| Renovaro Inc | 0.00 | -53.93m | 209.46m | 11.00 | -- | 1.24 | -- | -- | -0.7661 | -0.7661 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -37.06 | -27.81 | -41.75 | -28.44 | -- | -- | -- | -- | -- | -24.38 | 0.0405 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
| Conduit Pharmaceuticals Inc | -100.00bn | -100.00bn | 209.68m | -- | -- | -- | -- | -- | -- | -- | -- | -0.042 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Elevation Oncology Inc | 0.00 | -39.35m | 209.81m | 29.00 | -- | 2.62 | -- | -- | -1.03 | -1.03 | 0.00 | 1.47 | 0.00 | -- | -- | 0.00 | -42.35 | -- | -46.30 | -- | -- | -- | -- | -- | -- | -12.50 | 0.2889 | -- | -- | -- | 51.93 | -- | -- | -- |
| Werewolf Therapeutics Inc | 16.22m | -41.58m | 212.06m | 46.00 | -- | 1.80 | -- | 13.07 | -1.09 | -1.09 | 0.4343 | 2.72 | 0.087 | -- | 4.61 | 345,127.70 | -22.31 | -- | -25.22 | -- | -- | -- | -256.33 | -- | -- | -- | 0.2511 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
| Ovid Therapeutics Inc | 473.53k | -50.68m | 212.83m | 40.00 | -- | 2.71 | -- | 449.46 | -0.7174 | -0.7174 | 0.0067 | 1.11 | 0.0034 | -- | -- | 11,838.25 | -36.86 | -20.78 | -39.08 | -23.27 | -- | -- | -10,701.91 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
| G1 Therapeutics Inc | 84.04m | -30.59m | 213.83m | 100.00 | -- | 7.70 | -- | 2.54 | -0.6146 | -0.6146 | 1.55 | 0.531 | 0.6367 | 0.4852 | 6.07 | 840,410.00 | -23.18 | -47.06 | -30.95 | -52.64 | 91.89 | -- | -36.40 | -268.59 | 2.55 | -3.31 | 0.6084 | -- | 60.84 | -- | 67.49 | -- | -- | -- |
| Eliem Therapeutics Inc | 0.00 | -14.53m | 215.57m | 9.00 | -- | 1.93 | -- | -- | -0.5347 | -0.5347 | 0.00 | 3.84 | 0.00 | -- | -- | 0.00 | -12.55 | -- | -13.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
Data as of May 28 2024. Currency figures normalised to AVITA Medical Inc's reporting currency: US Dollar USD
22.22%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 1.62m | 6.29% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.36m | 5.27% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 941.04k | 3.65% |
| Geode Capital Management LLCas of 31 Mar 2024 | 543.02k | 2.11% |
| AWM Investment Co., Inc.as of 31 Mar 2024 | 496.95k | 1.93% |
| Silvercrest Asset Management Group LLCas of 31 Mar 2024 | 241.67k | 0.94% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 214.26k | 0.83% |
| CenterBook Partners LPas of 31 Mar 2024 | 145.35k | 0.56% |
| AQR Capital Management LLCas of 31 Mar 2024 | 90.60k | 0.35% |
| GlobeFlex Capital LPas of 31 Mar 2024 | 76.86k | 0.30% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
